microbiology
Can LAB exopolysaccharides act as therapeutic biomolecules?
Open access · cc by · source: Europe PMC
Among 10 strains, L. delbrueckii EPS5 had top yield and strong cytotoxicity (IC50 ~7.9–10.7 mg/ml) plus fibroblast-supportive effects.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Inspect source passages
Can LAB exopolysaccharides act as therapeutic biomolecules?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
EPS yields ranged 174.9–295.4 mg/l.
The EPS derived from bacteria ranged from 174.9 to 295.4 mg/l
EPS5 yield 295.4 ± 9.7 mg/l (highest).
L. delbrueckii ssp. bulgaricus DSM 20081 T produced the most EPS (EPS 5 , 295.4 ± 9.7)
Key findings
EPS yields 174.9–295.4 mg/l; DPPH scavenging 33.3–77% at 20 mg/ml; EPS5 most cytotoxic to MCF7/CaCo2/HepG2 and increased hPDLFC viability.
Methodology
Isolated EPS from LAB/Bb supernatants and tested concentration-dependent antioxidant, MTT antitumor, and human periodontal ligament fibroblast assays.
Limitations
In vitro only—does not prove clinical cancer therapy or safe replacement of chemotherapeutics.
Related papers in this topic
Same topic cluster — not a recommendation engine.